Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.

Aims: Real-world evidence on the safety profile and costs associated with immune thrombocytopenic purpura (ITP) treatment in adults is lacking. This study quantifies and compares adverse event (AE) crude rates and costs associated with ITP treatments as found in claims data.

Materials And Methods: A retrospective claims-based analysis was conducted using IMS Pharmetrics Plus database.

The economic impact of rapid Candida species identification by T2Candida among high-risk patients.

Introduction: This study estimates the cost-effectiveness and hospital budget impact of rapid candidemia identification using T2Candida, a novel diagnostic panel with same-day species-specific results.

Materials & Methods: A 1-year decision-tree model estimates hospital costs (2013 US$) and effects (candidemia-related deaths) for faster diagnostics versus blood culture (BC), accounting for disease prevalence, distribution of Candida species, test characteristics (sensitivity/specificity/time to result), antifungal medication and differential length-of-stay and mortality by appropriate treatment timing.

Results: The model estimates a hospital with 5100 annual high-risk patients could possibly save $5,858,448 with T2Candida versus BC, a 47.

Economic benefits of BIS-aided assessment of post-BC lymphedema in the United States.

Objectives: To estimate the economic outcomes associated with routine use of bioimpedance spectroscopy (BIS) to aid in the assessment of lymphedema following breast cancer (BC) treatment.

Study Design: Budget impact analysis for a hypothetical payer, comparing a "current standard assessment methods" scenario with a hypothetical scenario in which BIS is used routinely.

Methods: A payer-perspective decision model was built to calculate the 1-year budget impact of using either current standard methods or BISaided assessments for lymphedema in post-BC patients among a hypothetical payer population.